NASDAQ:OCGN
Ocugen Stock News
$1.59
-0.0800 (-4.79%)
At Close: May 10, 2024
Why Ocugen Stock Flopped Then Popped Today
11:02pm, Monday, 04'th Apr 2022 The Motley Fool
Good recent news about a pipeline drug trumped discouraging developments with a licensed coronavirus vaccine.
Hot Biotech Penny Stocks to Watch During the First Full Week of April
08:41pm, Monday, 04'th Apr 2022 PennyStocks
Can these biotech penny stocks continue to make gains?
The post Hot Biotech Penny Stocks to Watch During the First Full Week of April appeared first on Penny Stocks to Buy, Picks, News and Informati
What the WHO Snub Means For Ocugen Stock Investors?
07:55pm, Monday, 04'th Apr 2022
Add the World Health Organization's suspension of Covaxin to the list of troubles that are weighing down OCGN stock. The post What the WHO Snub Means For Ocugen Stock Investors?
Why Ocugen Stock Flopped Then Popped Today
07:02pm, Monday, 04'th Apr 2022
Good recent news about a pipeline drug trumped discouraging developments with a licensed coronavirus vaccine.
Hot Biotech Penny Stocks to Watch During the First Full Week of April
04:41pm, Monday, 04'th Apr 2022
Can these biotech penny stocks continue to make gains? The post Hot Biotech Penny Stocks to Watch During the First Full Week of April appeared first on Penny Stocks to Buy, Picks, News and Informati
Why Ocugen Stock Is Jumping Today
03:19pm, Friday, 01'st Apr 2022 The Motley Fool
The company dosed the first patient in a phase 1/2 study of its gene therapy candidate targeting a rare eye disease.
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration
11:37am, Friday, 01'st Apr 2022 GlobeNewswire Inc.
Announcement marks first clinical trial in humans of Ocugen’s modifier gene therapy platform Announcement marks first clinical trial in humans of Ocugen’s modifier gene therapy platform
Why Ocugen Stock Is Jumping Today
11:19am, Friday, 01'st Apr 2022
The company dosed the first patient in a phase 1/2 study of its gene therapy candidate targeting a rare eye disease.
3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street
09:06am, Wednesday, 30'th Mar 2022 The Motley Fool
Select analysts believe these fast-paced stocks can soar over the next 12 months.
It's Time to Get Clinical, Not Cynical, With Ocugen Stock
07:33am, Wednesday, 30'th Mar 2022
The selling pressure on OCGN stock has been as heavy as a rock, but worried shareholders should celebrate Ocugen's breakthrough moments. The post It's Time to Get Clinical, Not Cynical, With Ocugen St
Is Johnson & Johnson Setting a Dangerous Precedent for the Healthcare Industry?
11:00am, Saturday, 26'th Mar 2022 The Motley Fool
The company will likely save billions of dollars due to a controversial Texas bankruptcy law.
Is It Too Late to Buy Vaxart Stock?
03:37pm, Thursday, 24'th Mar 2022 The Motley Fool
The past 12 months have been difficult for the biotech stock.
Is It Time to Buy COVID-19 Vaccine Stocks Again?
09:56am, Thursday, 24'th Mar 2022 The Motley Fool
The picture is improving for vaccine stocks. But there's still a lot of uncertainty.
Is It Time to Buy COVID-19 Vaccine Stocks Again?
05:56am, Thursday, 24'th Mar 2022
The picture is improving for vaccine stocks. But there's still a lot of uncertainty.
Ocugen Announces Appointment of Marna C. Whittington, PhD, to Board of Directors
11:44am, Wednesday, 23'rd Mar 2022 GlobeNewswire Inc.
MALVERN, Pa., March 23, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel gene therapies, bi
